Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Lipton, Jeffrey Howard
  • Hughes, Timothy P
  • Leber, Brian
  • De Souza, Carmino
  • Dorlhiac-Llacer, Pedro E
  • Steegmann, Juan Luis
  • Guerci-Bresler, Agnes
  • Schwarer, Anthony P
  • Cervantes, Francisco
  • Reynolds, John
  • Collins, LaTonya R
  • Szczudlo, Tomasz K
  • Spector, Nelson

publication date

  • May 20, 2012